GlassScriptPhysician profile
Michelle R Kirk
NPI 1356792014
$58,251.50
in general payments reported to CMS, 2019-2025
19 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $57K · 2023: $253 · 2024: $461 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57,027.98 | 2022-2025 | |
| Abbvie INC. | $414.40 | 2022-2025 | |
| Novo Nordisk INC | $131.51 | 2022-2025 | Rybelsus, Ozempic |
| Amgen INC. | $126.27 | 2022-2024 | Otezla, Repatha, Evenity |
| Sumitomo Pharma America, INC. | $92.89 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $91.47 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $59.65 | 2022-2025 | |
| Corium, LLC | $53.86 | 2022-2023 | Adlarity |
| Sunovion Pharmaceuticals INC. | $45.92 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.26 | 2022 | |
| Astellas Pharma US INC | $36.01 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $35.76 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $15.43 | 2023 | Januvia, Steglatro, Belsomra |
| Astrazeneca Pharmaceuticals LP | $14.89 | 2025 | Airsupra |
| Dexcom, INC. | $14.21 | 2025 | Dexcom G6 Transmitter |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $13.74 | 2023 | |
| Exact Sciences Corporation | $13.20 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $13.05 | 2023 | Xarelto |
| Glaxosmithkline, LLC. | $13.00 | 2023 | Bexsero, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.